Complete Story


Despite Risks and Limitations, FDA Advisors Strongly Back New Alzheimer’s Drug

The drug, donanemab, is effective at slowing down the disease

Advisors to the Food and Drug Administration (FDA) have recommended unanimously that the agency approve the Alzheimer’s drug donanemab.

At a meeting Monday, the Peripheral and Central Nervous System Drugs Advisory Committee voted 11-0 that donanemab is effective at slowing down Alzheimer’s in the disease’s early stages and that the drug’s benefits outweigh its risks.

All 11 committee members also recommended that doctors and patients have the option of halting monthly infusions if tests show that most amyloid plaques — a hallmark of Alzheimer’s — have been removed from the brain.

Please select this link to read the complete article from NPR.

Printer-Friendly Version